NDA Board of Trustees terminates iCore Rx endorsement.
The NDA endorsed iCore in early 2024 as a result of the prescription mandate. Several other states also receives a small endorsement fee. As part of the NDA endorsement of iCore, the NDA was scheduled to recieve a small endorseament payment from iCore. To date, the NDA has only received one payment for the first 2 Quarters of 2024. When the NDA polled the others states endorsing iCore, none of them had been paid for the last half of 2024 either.
NDA letter to terminate iCore Endorsement
Question: Is a dentist required to check the PDMP before prescribing a controlled substance?
Answer: 471 NAC 18.009. PRESCRIPTION DRUG MONITORING PROGRAM.
009.01 GENERAL REQUIREMENT. Each provider prescribing a controlled substance in Nebraska to a Medicaid client must check the prescription drug monitoring program established under Neb. Rev. Stat. § 71-2454 before prescribing a schedule II medication and at dosage adjustment. Provider may delegate checking of the prescription drug monitoring program to a delegate as defined in Neb. Rev. Stat. § 71-2454 (14)(c).
009.02 EXCEPTION. Good faith exceptions must be documented in the client’s medical record and provided upon request to the Department. These requirements do not include a prescription to a client as set forth under 42 U.S.C. Sec. 1396w-3a and to a resident of a facility where schedule II medications are dispensed to a client through a single pharmacy.
